Thus, the expression of ANGPTL3 could serve as an independent predictor of the response to sorafenib and the subcellular distribution of FAK, together with the expression of p53 might predict acquired resistance to sorafenib in RCC patients. This evidence concerns the gene ANGPTL3 and renal cell carcinoma.